INTERNATIONAL CANCER TREATMENT
WHY CHINA LEADS THE WORLD

Seeking cancer treatment abroad is never a casual decision — it reflects genuine unmet need: treatments unavailable at home, prohibitive costs, need for specialist expertise, or access to clinical trials that represent the only available advanced option.

• Access to Unavailable Treatments

  CAR-T therapy, gene therapy, proton beam radiation, and specific clinical trials are only available in countries with advanced research infrastructure. For patients from South Asia, the Middle East, Africa, and Southeast Asia, China is often the nearest accessible source.

• Cost: Same Quality at a Fraction of the Price

  CAR-T therapy costs USD 400,000–500,000 in the US. In China, comparable therapy at leading centres may cost 5–10x less. Immunotherapy, targeted therapy, and stem cell transplantation are significantly cheaper in China without compromising quality at top-tier hospitals.

• Second Opinions and Specialist Expertise

  Many international patients seek second opinions — not treatment relocation. A consultation with a specialist who has seen thousands of a particular cancer type often reveals treatment options missed at the initial centre, or confirms the current plan with confidence.

• Clinical Trial Access

  China has one of the most active oncology trial ecosystems globally for CAR-T, immunotherapy, targeted therapy, and gene therapy. For patients who have exhausted standard options, an enrolling Chinese trial may be the most advanced available therapy — often at no cost for the experimental agent.

China's position as the world's leading international cancer treatment destination is not marketing — it reflects specific, measurable clinical capabilities unavailable elsewhere at comparable cost and access.

“China is the only country in the world where the first commercial cancer gene therapy is approved, more CAR-T trials are running than anywhere else, and proton beam centres are expanding rapidly.”

• World's Most Active CAR-T Ecosystem

  China has the highest number of registered CAR-T clinical trials globally. Multiple NMPA-approved CAR-T products are commercially available. For patients with refractory B-cell lymphoma, myeloma, or ALL, China offers the broadest range of CAR-T options at 5–10x lower cost than the US.

• First Commercial Cancer Gene Therapy (Gendicine)

  Gendicine (recombinant adenovirus-p53) is the world's first approved cancer gene therapy, available commercially in China since 2003 for head and neck squamous cell carcinoma. No equivalent commercial approval exists in the US or Europe. Used in combination with radiotherapy and chemotherapy.

• Proton and Heavy Ion Therapy

  SPHIC (Shanghai Proton and Heavy Ion Centre) offers both proton beam and carbon ion therapy — one of only a small number of carbon ion centres globally. Costs are a fraction of equivalent centres in Japan or Germany, with comparable technical specifications and clinical outcomes.

• Precision Oncology and NGS Infrastructure

  China has a mature NGS testing infrastructure, with multiple NMPA-approved comprehensive genomic profiling platforms. Biomarker-driven therapy selection — essential for targeted therapy and immunotherapy matching — is the standard of care at leading Chinese oncology centres.

Indicative costs at leading Chinese centres vs equivalent centres in the US. Actual costs vary by centre, treatment regimen, and individual clinical complexity.

China's top-tier cancer centres meet international standards for oncology care, clinical trial infrastructure, and international patient services.

From medical record preparation to treatment completion — the step-by-step journey for international patients.

1. 1

   Medical Record Preparation

   Compile all pathology reports, imaging (CT, PET-CT, MRI), molecular testing (NGS), blood work, and treatment history. CancerFax translates and formats records for submission to Chinese specialist teams.

2. 2

   Hospital and Specialist Matching

   Based on cancer type, stage, and treatment history, CancerFax identifies the most appropriate hospital and specialist team — not just a "good hospital" but the right expert for the specific diagnosis.

3. 3

   Remote Pre-Consultation

   Video consultation with the Chinese specialist before travel to confirm eligibility, treatment plan, and logistics — avoiding unnecessary travel if the patient is not a suitable candidate for the proposed treatment.

4. 4

   Medical Visa and Travel Logistics

   CancerFax coordinates the medical visa invitation letter, arranges accommodation near the treating centre, and provides airport transfer and in-country orientation for the patient and family.

5. 5

   In-Country Support and Interpretation

   Mandarin-English (and other language) medical interpretation for all clinical consultations, daily support during treatment, and family communication throughout the stay.

6. 6

   Post-Treatment Handover

   Translation of all Chinese treatment records, coordination of handover to the home oncologist, and support for the ongoing monitoring period — much of which can be conducted remotely.

Each page covers one international cancer treatment topic in depth.

Frequently Asked Questions